Long-term kidney function in children with Wilms tumour and constitutional WT1 pathogenic variant

被引:8
|
作者
Falcone, Maria Pia [1 ,2 ]
Pritchard-Jones, Kathryn [1 ]
Brok, Jesper [1 ,3 ]
Mifsud, William [1 ]
Williams, Richard D. [1 ]
Nakata, Kayo [1 ]
Tugnait, Suzanne [1 ]
Al-Saadi, Reem [1 ,4 ]
Side, Lucy [5 ]
Anderson, John [1 ]
Duncan, Catriona [1 ]
Marks, Stephen D. [1 ,6 ]
Bockenhauer, Detlef [6 ,7 ]
Chowdhury, Tanzina [1 ]
机构
[1] Great Ormond St Hosp Sick Children, NIHR Great Ormond St Hosp Biomed Res Ctr, UCL Inst Child Hlth, Dept Paediat Oncol, London, England
[2] Univ Foggia, Paediat Residency Program, Foggia, Italy
[3] Copenhagen Univ Hosp, Rigshosp, Dept Paediat Haematol & Oncol, Copenhagen, Denmark
[4] Great Ormond St Hosp Children NHS Fdn Trust, Dept Histopathol, London, England
[5] Great Ormond St Hosp Children NHS Fdn Trust, Dept Clin Genet, London, England
[6] Great Ormond St Hosp Children NHS Fdn Trust, Dept Paediat Nephrol, London, England
[7] UCL Dept Renal Med, London, England
关键词
Wilms tumour; WT1 pathogenic variant; Kidney function; NEPHRON-SPARING SURGERY; DENYS-DRASH-SYNDROME; STAGE RENAL-DISEASE; GERMLINE MUTATIONS; SUPPRESSOR GENE; RISK-FACTORS; FREQUENCY;
D O I
10.1007/s00467-021-05125-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Wilms tumour (WT) survivors, especially patients with associated syndromes or genitourinary anomalies due to constitutional WT1 pathogenic variant, have increased risk of kidney failure. We describe the long-term kidney function in children with WT and WT1 pathogenic variant to inform the surgical strategy and oncological management of such complex children. Methods Retrospective analysis of patients with WT and constitutional WT1 pathogenic variant treated at a single centre between 1993 and 2016, reviewing genotype, phenotype, tumour histology, laterality, treatment, patient survival, and kidney outcome. Results We identified 25 patients (60% male, median age at diagnosis 14 months, range 4-74 months) with WT1 deletion (4), missense (2), nonsense (8), frameshift (7), or splice site (4) pathogenic variant. Thirteen (52%) had bilateral disease, 3 (12%) had WT-aniridia, 1 had incomplete Denys-Drash syndrome, 11 (44%) had genitourinary malformation, and 10 (40%) had no phenotypic anomalies. Patient survival was 100% and 3 patients were in remission after relapse at median follow-up of 9 years. Seven patients (28%) commenced chronic dialysis of which 3 were after bilateral nephrectomies. The overall kidney survival for this cohort as mean time to start of dialysis was 13.38 years (95% CI: 10.3-16.4), where 7 patients experienced kidney failure at a median of 5.6 years. All of these 7 patients were subsequently transplanted. In addition, 2 patients have stage III and stage IV chronic kidney disease and 12 patients have albuminuria and/or treatment with ACE inhibitors. Four patients (3 frameshift; 1 WT1 deletion) had normal blood pressure and kidney function without proteinuria at follow-up from 1.5 to 12 years. Conclusions Despite the known high risk of kidney disease in patients with WT and constitutional WT1 pathogenic variant, nearly two-thirds of patients had sustained native kidney function, suggesting that nephron-sparing surgery (NSS) should be attempted when possible without compromising oncological risk. Larger international studies are needed for accurate assessment of WT1genotype-kidney function phenotype correlation.
引用
收藏
页码:821 / 832
页数:12
相关论文
共 50 条
  • [21] Transcriptional regulation by the Wilms' tumour suppressor protein WT1
    Wagner, KJ
    Roberts, SGE
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2004, 32 : 932 - 935
  • [22] Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas
    Coosemans, A.
    Nik, S. Amini
    Caluwaerts, S.
    Lambin, S.
    Verbist, G.
    Van Bree, R.
    Schelfhout, V.
    de Jonge, E.
    Dalle, I.
    Jacomen, G.
    Cassiman, J. J.
    Moerman, Ph.
    Vergote, I.
    Amant, F.
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (10) : 1630 - 1637
  • [23] The Wilms' tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression
    Wagner, Kay-Dietrich
    Cherfils-Vicini, Julien
    Hosen, Naoki
    Hohenstein, Peter
    Gilson, Eric
    Hastie, Nicholas D.
    Michiels, Jean-Francois
    Wagner, Nicole
    NATURE COMMUNICATIONS, 2014, 5
  • [24] The Wilms’ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression
    Kay-Dietrich Wagner
    Julien Cherfils-Vicini
    Naoki Hosen
    Peter Hohenstein
    Eric Gilson
    Nicholas D. Hastie
    Jean-François Michiels
    Nicole Wagner
    Nature Communications, 5
  • [25] Familial Wilms tumour resulting from WT1 mutation:: intronic polymorphism causing artefactual constitutional homozygosity
    Pritchard-Jones, K
    Rahman, N
    Gerrard, M
    Variend, D
    King-Underwood, L
    JOURNAL OF MEDICAL GENETICS, 2000, 37 (05) : 377 - 379
  • [26] Long-term effects of Wilms tumour therapy on renal function
    Aoife M. Waters
    Kathy Pritchard-Jones
    Nature Reviews Urology, 2015, 12 : 423 - 424
  • [27] Splicing of Exon 5 in the WT1 gene is disrupted in Wilms' tumour
    Simms, LA
    Algar, EM
    Smith, PJ
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (13-14) : 2270 - 2276
  • [28] The role of the Wilms' tumour-suppressor protein WT1 in apoptosis
    Hartkamp, Joerg
    Roberts, Stefan G. E.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2008, 36 : 629 - 631
  • [29] Nuclear Transport of Wilms' Tumour Protein Wt1 Involves Importins α and β
    Depping, Reinhard
    Schindler, Susann G.
    Jacobi, Charlotte
    Kirschner, Karin M.
    Scholz, Holger
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2012, 29 (1-2) : 223 - 232
  • [30] Wilms' tumour and the WT1 tumour supressor gene: Disease, development, evolution and multifunctionality
    Hastie, N
    JOURNAL OF MEDICAL GENETICS, 2001, 38 : S30 - S30